Narjust Florez
MD
Associate Director of the Cancer Care Equity Program and Assistant Professor of Medicine
Dana-Farber Cancer Institute
Harvard Medical School
Sep 09, 2024
Episode
242
Soundcloud
Share
In this special WCLC 2024 episode of Lung Cancer Considered, host Dr. Narjust Florez discusses daily highlights from the conference. Dr. Xiuning Le reports updated results of BAY 292708, and Dr. Gerrina Ruiter summarizes the Beamion LUNG-1 study, both of which evaluate the efficacy of therapies for patients with HER2-Mutant NSCLC. Dr. Fiona Hegi-Johnson adds her perspective as a discussant of the POLESTAR trial evaluating EGFR therapy after chemoradiation in stage III unresectable NSCLC.
Guest
Xiuning Le
MD, PhD
Associate Professor in the Department of Thoracic and Head and Neck Medical Oncology
University of Texas MD Anderson Cancer Center
Gerrina Ruiter
M.D., Ph.D.
Pulmonologist Specialized in Thoracic Oncology
Netherlands Cancer Institute
Fiona Hegi-Johnson
MD
Senior Research Fellow
University of Melbourne
